Viral Vector Manufacturing Market Size, Share & Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Viral Vector Manufacturing Market Size Analysis

Global Viral Vector Manufacturing Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Viral Vectors
    1. By Value
    2. Retroviruses
      1. Retroviruses By Value
    3. Adenoviruses
      1. Adenoviruses By Value
    4. Adeno-associated viruses (AAVs)
      1. Adeno-associated viruses (AAVs) By Value
    5. Lentiviruses
      1. Lentiviruses By Value
    6. Others
      1. Others By Value
  3. Plasmid DNA
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream Manufacturing
    1. By Value
    2. Vector Amplification, Editing and Expansion
      1. Vector Amplification, Editing and Expansion By Value
    3. Vector Recovery/Harvesting
      1. Vector Recovery/Harvesting By Value
  3. Downstream Manufacturing
    1. By Value
    2. Purification
      1. Purification By Value
    3. Fill Finish
      1. Fill Finish By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Gene Therapy
    1. By Value
  3. Vaccinology
    1. By Value
4. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
5. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Academics and Research Institutes
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Viral Vectors
    1. By Value
    2. Retroviruses
      1. Retroviruses By Value
    3. Adenoviruses
      1. Adenoviruses By Value
    4. Adeno-associated viruses (AAVs)
      1. Adeno-associated viruses (AAVs) By Value
    5. Lentiviruses
      1. Lentiviruses By Value
    6. Others
      1. Others By Value
  3. Plasmid DNA
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream Manufacturing
    1. By Value
    2. Vector Amplification, Editing and Expansion
      1. Vector Amplification, Editing and Expansion By Value
    3. Vector Recovery/Harvesting
      1. Vector Recovery/Harvesting By Value
  3. Downstream Manufacturing
    1. By Value
    2. Purification
      1. Purification By Value
    3. Fill Finish
      1. Fill Finish By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Gene Therapy
    1. By Value
  3. Vaccinology
    1. By Value
4. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
5. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Academics and Research Institutes
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Viral Vectors
    1. By Value
    2. Retroviruses
      1. Retroviruses By Value
    3. Adenoviruses
      1. Adenoviruses By Value
    4. Adeno-associated viruses (AAVs)
      1. Adeno-associated viruses (AAVs) By Value
    5. Lentiviruses
      1. Lentiviruses By Value
    6. Others
      1. Others By Value
  3. Plasmid DNA
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream Manufacturing
    1. By Value
    2. Vector Amplification, Editing and Expansion
      1. Vector Amplification, Editing and Expansion By Value
    3. Vector Recovery/Harvesting
      1. Vector Recovery/Harvesting By Value
  3. Downstream Manufacturing
    1. By Value
    2. Purification
      1. Purification By Value
    3. Fill Finish
      1. Fill Finish By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Gene Therapy
    1. By Value
  3. Vaccinology
    1. By Value
4. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
5. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Academics and Research Institutes
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Viral Vectors
    1. By Value
    2. Retroviruses
      1. Retroviruses By Value
    3. Adenoviruses
      1. Adenoviruses By Value
    4. Adeno-associated viruses (AAVs)
      1. Adeno-associated viruses (AAVs) By Value
    5. Lentiviruses
      1. Lentiviruses By Value
    6. Others
      1. Others By Value
  3. Plasmid DNA
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream Manufacturing
    1. By Value
    2. Vector Amplification, Editing and Expansion
      1. Vector Amplification, Editing and Expansion By Value
    3. Vector Recovery/Harvesting
      1. Vector Recovery/Harvesting By Value
  3. Downstream Manufacturing
    1. By Value
    2. Purification
      1. Purification By Value
    3. Fill Finish
      1. Fill Finish By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Gene Therapy
    1. By Value
  3. Vaccinology
    1. By Value
4. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
5. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Academics and Research Institutes
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Viral Vectors
  1. By Value
  2. Retroviruses
    1. Retroviruses By Value
  3. Adenoviruses
    1. Adenoviruses By Value
  4. Adeno-associated viruses (AAVs)
    1. Adeno-associated viruses (AAVs) By Value
  5. Lentiviruses
    1. Lentiviruses By Value
  6. Others
    1. Others By Value
3. Plasmid DNA
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream Manufacturing
  1. By Value
  2. Vector Amplification, Editing and Expansion
    1. Vector Amplification, Editing and Expansion By Value
  3. Vector Recovery/Harvesting
    1. Vector Recovery/Harvesting By Value
3. Downstream Manufacturing
  1. By Value
  2. Purification
    1. Purification By Value
  3. Fill Finish
    1. Fill Finish By Value
By Application
1. Introduction
  1. Application By Value
2. Gene Therapy
  1. By Value
3. Vaccinology
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Academics and Research Institutes
  1. By Value
4. Others
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Viral Vectors
    1. By Value
    2. Retroviruses
      1. Retroviruses By Value
    3. Adenoviruses
      1. Adenoviruses By Value
    4. Adeno-associated viruses (AAVs)
      1. Adeno-associated viruses (AAVs) By Value
    5. Lentiviruses
      1. Lentiviruses By Value
    6. Others
      1. Others By Value
  3. Plasmid DNA
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream Manufacturing
    1. By Value
    2. Vector Amplification, Editing and Expansion
      1. Vector Amplification, Editing and Expansion By Value
    3. Vector Recovery/Harvesting
      1. Vector Recovery/Harvesting By Value
  3. Downstream Manufacturing
    1. By Value
    2. Purification
      1. Purification By Value
    3. Fill Finish
      1. Fill Finish By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Gene Therapy
    1. By Value
  3. Vaccinology
    1. By Value
4. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
5. By End User
  1. Introduction
    1. End User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Academics and Research Institutes
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Viral Vector Manufacturing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Merck GA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Lonza
BD
Fujifilm Diosynth biotechnologies USA Inc.
Brammer Bio
Cell Therapy Catapult Limited
Waisman Biomanufacturing
GENEZEN LABORATORIES
Yposkesi Inc.
REGENXBIO Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment